The Latest Breaking News from Pfizer Inc

Pfizer Inc (NYSE:PFE) has submitted a new drug application to the FDA for the approval of Paxlovid for patients at high risk for progression to severe illness from COVID-19.  Paxlovid is currently authorized for emergency use to treat mild-to-moderate COVID-19 in adults and pediatric patients at high risk for progression to severe COVID-19,…

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have announced a new vaccine supply agreement with the U.S. government. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult omicron-adapted COVID-19 vaccines, subject to the FDA authorization.  The doses are planned to be delivered…

Anthony Fauci, the chief medical adviser to President Joe Biden, suffered a rebound of COVID-19 symptoms after taking Pfizer Inc.’s antiviral Paxlovid.

COVID-19 shots from Pfizer Inc. and Moderna Inc. should be updated to include components that target the highly transmissible omicron variant, the version of the virus that causes most of the world’s cases, U.S. regulatory advisers said.

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant.  Pfizer holds a 25%…

The U.S. government will provide up to $75 million to expand U.K.-listed Croda International Plc's (OTC:COIHF) U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines. Croda will also invest up to $58 million. The investment will be used to establish a new lipid facility in Lamar,…

Infants and toddlers in the U.S. are now able to be vaccinated against COVID-19 after shots from Moderna Inc. and Pfizer Inc. won support from health advisers on Saturday.

The FDA has granted emergency use authorization (EUA) to Pfizer Inc (NYSE:PFE) and BioNTech SE's (NASDAQ:BNTX) COVID-19 Vaccine as a three 3-µg dose series for children six months through 4 years of age.  Based on safety, tolerability, and immunogenicity data, the 3-µg dose was carefully selected as the preferred dose for children under five. The EUA…

COVID vaccines for children ages 5 and under from Pfizer Inc. and Moderna Inc. received authorization from U.S. regulators, meaning almost all of the American population can soon get protected against COVID-19 disease.

As Bavarian Nordic A/S (OTC: BVNRY) was in the headlines recently due to the smallpox vaccine amid rising cases of monkeypox, the company is also getting ready to evaluate its COVID-19 booster, ABNCoV2, in a pivotal study. ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark using their proprietary capsid virus-like…

Akero Therapeutics Inc (NASDAQ:AKRO) announced a $25 million equity investment by Pfizer Inc (NYSE:PFE) at $9.90 per share.  The company also announced a term loan facility providing Akero with access to up to $100 million from Hercules Capital Inc (NYSE:HTGC), of which $10 million will be drawn at transaction close.  Together with existing cash, proceeds will support…